1. Home
  2. KTTA vs LCFY Comparison

KTTA vs LCFY Comparison

Compare KTTA & LCFY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KTTA
  • LCFY
  • Stock Information
  • Founded
  • KTTA 2020
  • LCFY 2009
  • Country
  • KTTA United States
  • LCFY Australia
  • Employees
  • KTTA N/A
  • LCFY 26
  • Industry
  • KTTA Biotechnology: Pharmaceutical Preparations
  • LCFY
  • Sector
  • KTTA Health Care
  • LCFY
  • Exchange
  • KTTA Nasdaq
  • LCFY Nasdaq
  • Market Cap
  • KTTA 5.5M
  • LCFY 5.9M
  • IPO Year
  • KTTA 2021
  • LCFY 2022
  • Fundamental
  • Price
  • KTTA $0.68
  • LCFY $4.50
  • Analyst Decision
  • KTTA
  • LCFY
  • Analyst Count
  • KTTA 0
  • LCFY 0
  • Target Price
  • KTTA N/A
  • LCFY N/A
  • AVG Volume (30 Days)
  • KTTA 142.8K
  • LCFY 5.0M
  • Earning Date
  • KTTA 08-12-2025
  • LCFY 07-22-2025
  • Dividend Yield
  • KTTA N/A
  • LCFY N/A
  • EPS Growth
  • KTTA N/A
  • LCFY N/A
  • EPS
  • KTTA N/A
  • LCFY N/A
  • Revenue
  • KTTA N/A
  • LCFY $2,668,385.00
  • Revenue This Year
  • KTTA N/A
  • LCFY N/A
  • Revenue Next Year
  • KTTA N/A
  • LCFY N/A
  • P/E Ratio
  • KTTA N/A
  • LCFY N/A
  • Revenue Growth
  • KTTA N/A
  • LCFY N/A
  • 52 Week Low
  • KTTA $0.67
  • LCFY $2.50
  • 52 Week High
  • KTTA $7.50
  • LCFY $13.98
  • Technical
  • Relative Strength Index (RSI)
  • KTTA 32.67
  • LCFY 52.74
  • Support Level
  • KTTA $0.67
  • LCFY $4.28
  • Resistance Level
  • KTTA $0.77
  • LCFY $5.40
  • Average True Range (ATR)
  • KTTA 0.04
  • LCFY 1.17
  • MACD
  • KTTA 0.01
  • LCFY 0.08
  • Stochastic Oscillator
  • KTTA 14.02
  • LCFY 20.23

About KTTA Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).

About LCFY Locafy Limited

Locafy Ltd is focused on commercializing its Software as a Service (SaaS) online publishing technology platform. Its platform enables the ability to publish almost any type of content to almost any device that uses a web browser to display web content. The firm has two operating segments: Publishing and SEO agency. Under the Publishing segment are products and services that the Company offers that are related to digital properties (i.e. mastheads) that it owns e.g. business data published on Hotfrog, advertising placed on AussieWeb, articles published on scoop.com.au. In contrast, under the SEO Agency segment are products and services that are applied to digital properties that are owned and operated by third parties. It derives a majority of its revenue in North America from SEO Agency.

Share on Social Networks: